Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05621655
PHASE2

Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers

Sponsor: MAXVAX Biotechnology Limited Liability Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the immunogenicity, safety and immune persistence of recombinant trivalent rotavirus subunit vaccine in healthy infants aged 6-12 weeks and healthy toddlers aged 7-71 months.

Official title: A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Subunit Rotavirus Vaccine in Healthy Infants Aged 6-12 Weeks and Healthy Toddlers Aged 7-71 Months

Key Details

Gender

All

Age Range

6 Weeks - 71 Months

Study Type

INTERVENTIONAL

Enrollment

1512

Start Date

2023-01-08

Completion Date

2024-12

Last Updated

2024-11-20

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine

0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

BIOLOGICAL

High dose Recombinant Trivalent Subunit Rotavirus Vaccine

0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

BIOLOGICAL

Placebo

0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.

Locations (2)

Shangqiu Liangyuan District Center for Disease Control and Prevention

Shangqiu, Henan, China

Ningling County Center for Disease Control and Prevention

Shangqiu, Henan, China